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Statement of translational relevance (119/150 words) 72 
Early identification of the AKT1E17K genomic biomarker, coupled with a novel targeted and 73 
non-myeloablative agent, could enhance treatment options in AKT1E17K-mutant ER+ 74 
metastatic breast cancer. In this first-in-human, multipart, Phase I expansion study, 75 
capivasertib alone or in combination with fulvestrant was well tolerated and showed 76 
promising anticancer activity in such a patient population, including those with prior disease 77 
progression on fulvestrant. Tolerability and efficacy appeared marginally better with 78 
combination therapy, suggesting that combination AKT and ER inhibition is an effective 79 
targeted therapy approach for AKT1E17K-mutant ER+ metastatic breast cancer. Furthermore, 80 
our data provide a rationale for incorporating potentially actionable alterations in breast 81 
cancer into diagnostic testing algorithms for the early identification of these alterations in the 82 
metastatic disease course.  83 
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Abstract (250/250 words) 84 
Purpose: The activating mutation AKT1E17K occurs in ~7% of ER+ metastatic breast cancer 85 
(MBC). We report, from a multipart, first-in-human, Phase I study (NCT01226316), tolerability 86 
and activity of capivasertib, an oral AKT inhibitor, as monotherapy or combined with fulvestrant 87 
in expansion cohorts of AKT1E17K-mutant ER+ MBC patients. 88 
 89 
Patients and Methods:  Patients with an AKT1E17K mutation, detected by local (NGS) or central 90 
(plasma-based BEAMing) testing, received capivasertib 480 mg bid, 4 days on, 3 days off, 91 
weekly or 400 mg bid combined with fulvestrant at the labeled dose. Study endpoints included 92 
safety, objective response rate (ORR; RECIST v1.1), progression-free survival (PFS) and 93 
clinical benefit rate at 24 weeks (CBR24). Biomarker analyses were conducted in the 94 
combination cohort. 95 
 96 
Results: From October 2013 to August 2018, 63 heavily pretreated patients received 97 
capivasertib (20 monotherapy, 43 combination). ORR was 20% with monotherapy, and within 98 
the combination cohort was 36% in fulvestrant-pretreated and 20% in fulvestrant-naïve patients, 99 
although this latter group may have had more aggressive disease at baseline. AKT1E17K 100 
mutations were detectable in plasma by BEAMing (95%, 41/43), ddPCR (80%, 33/41) and NGS 101 
(76%, 31/41). A ≥50% decrease in AKT1E17K at cycle 2 day 1 was associated with improved 102 
PFS. Combination therapy appeared more tolerable than monotherapy (most frequent grade ≥3 103 
adverse events: rash [9% vs 20%], hyperglycemia [5% vs 30%], diarrhea [5% vs 10%]). 104 
 105 
Conclusions: Capivasertib demonstrated clinically meaningful activity in heavily pretreated 106 
AKT1E17K-mutant ER+ MBC patients, including those with prior disease progression on 107 




Estrogen-receptor-positive (ER+), HER2-negative (HER2–) breast cancer is the most common 110 
subtype of metastatic breast cancer (MBC), accounting for >400,000 deaths worldwide every 111 
year (1, 2). The incorporation of inhibitors of mTOR and CDK4/6 into endocrine therapy has led 112 
to substantial improvements in patient outcomes (3-8). However, once endocrine-therapy-113 
refractory disease inevitably develops, chemotherapy remains the only approved option, and 114 
little progress has been made for this phase of illness. Given the successes of genomically 115 
selected therapy in other solid tumors harboring driver alterations (9, 10), widescale efforts to 116 
identify therapeutically actionable genomic subsets of breast cancer have been undertaken (11-117 
15). 118 
 119 
The PI3K pathway is one of the most commonly activated signaling pathways in ER+ breast 120 
cancer (16). The efficacy of an isoform-selective PI3K inhibitor in PIK3CA-mutant ER+ HER2– 121 
MBC was recently demonstrated in a Phase III study (17), providing proof of concept that this 122 
pathway is therapeutically targetable in this clinical context. While PIK3CA mutations represent 123 
the most common mechanism of PI3K pathway activation, in an estimated 7% of ER+ breast 124 
cancers, pathway activation can occur through mutation in AKT1 (15), predominantly AKT1E17K 125 
(~80%). In such cases, signaling is constitutively activated through pathologic localization of 126 
AKT1 to the plasma membrane (18-20). Although, in the largest comparative analysis of 127 
matched AKT1-mutant and wild-type ER+ MBC patients, there did not appear to be significant 128 
differences in terms of overall survival or duration on endocrine- and CDK4/6 inhibitor therapy, 129 
patients with AKT1-mutant disease were, however, noted to have significantly longer durations 130 
on MTOR inhibitor therapy (21), indicative of the potential therapeutic relevance of this alteration 131 
in breast cancer. Moreover, AKT1E17K-mutant tumors may not be amenable to PI3K inhibitors 132 
owing to their PI3K-independent mechanism of AKT activation (15, 22-27). As such, patients 133 
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harboring AKT1E17K mutations represent a genomic subset of ER+ MBC in need of unique 134 
therapeutic approaches. 135 
 136 
Capivasertib (AZD5363) is an oral, potent, selective ATP-competitive pan-AKT kinase inhibitor 137 
(28). We previously explored the efficacy of capivasertib monotherapy in patients with advanced 138 
solid tumors harboring an AKT1E17K mutation, including 20 patients with ER+ MBC, whereby the 139 
objective response rate (ORR) was 20% and median progression-free survival (PFS) was 5.5 140 
months (29). Consistent with this observation, similar capivasertib monotherapy efficacy was 141 
recently reported in the AKT1-mutant arm of the NCI-MATCH study in multiple solid tumors, 142 
including ER+ MBC (30).  143 
 144 
As observed with isoform-selective PI3K inhibitors, preclinical data with capivasertib suggests 145 
that efficacy in ER+ breast cancer may be limited in part by a compensatory increase in ER-146 
dependent gene transcription, suggesting that combination strategies may be required to 147 
maximize therapeutic efficacy in this subtype (31-33). Accordingly, preclinical models suggest 148 
synergistic efficacy when capivasertib is combined with fulvestrant, an ER antagonist and 149 
degrader approved for the treatment of ER+ MBC (32). Therefore, to clinically explore the 150 
hypothesis that simultaneous inhibition of AKT and ER would enhance antitumor efficacy in 151 
AKT1E17K-mutant ER+ breast cancer, we amended the prior Phase I study to include a 152 
multicohort expansion of the combination of capivasertib and fulvestrant. 153 
 154 
Here we present the safety, efficacy and biomarker analysis for the combination of capivasertib 155 
and fulvestrant in ER+, AKT1E17K-mutant MBC. To provide additional clinical context, final 156 




Study Design and Participants 159 
The protocol started as the first-in-human, multipart, Phase I, dose- and schedule-finding study 160 
of capivasertib. Following identification of a recommended Phase II dose, the safety and 161 
efficacy of capivasertib was further explored in multiple molecularly and histologically defined 162 
Phase I expansion cohorts recruited at study centers worldwide. Results of the initial dose 163 
escalation, pharmacodynamic cohort, and monotherapy efficacy in patients with advanced solid 164 
tumors, as well as those with activating PIK3CA or AKT1 mutations, have previously been 165 
reported (29, 34). The study start date was December 2010 and the estimated completion date 166 
is December 2019 (ClinicalTrials.gov, NCT01226316). 167 
 168 
Here we report the results of capivasertib plus fulvestrant in patients with advanced ER+ breast 169 
cancer with AKT1E17K mutations, including patients without prior fulvestrant therapy (fulvestrant-170 
naïve cohort) and those who received prior fulvestrant (fulvestrant-pretreated cohort; Figure 1). 171 
Updated and final efficacy data of capivasertib monotherapy in ER+ AKT1E17K-mutant breast 172 
cancer are also included.  173 
 174 
Eligible patients had histologically confirmed ER+, HER2– MBC with progressive measurable 175 
disease (according to Response Evaluation Criteria in Solid Tumors [RECIST] v1.1) that was 176 
refractory to standard therapies or for which no standard therapies exist, and they harbored an 177 
AKT1E17K tumor mutation. Qualifying AKT1E17K mutations were identified either through local 178 
testing, as routinely obtained at participating sites, or via a central plasma-based analysis using 179 
the OncoBEAM™ BEAMing (beads, emulsification, amplification, and magnetics) assay with 180 
previously described methods (11). Specifically, local testing employed various next-generation 181 
sequencing (NGS)-based assays, in accordance with local standard practice without any 182 
threshold for positivity mandated by AstraZeneca for enrollment. Central plasma-based 183 
 9 
 
BEAMing analysis with the OncoBEAM™ assay used a 0.02% threshold of analyzed AKT1 184 
copies containing the E17K mutation for positivity (35). Further inclusion criteria included age 18 185 
years or older and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 186 
1. Key exclusion criteria included active central nervous system metastases, prior treatment with 187 
catalytic AKT inhibitors (prior exposure to all other agents in the PI3K/AKT/mTOR pathway, 188 
including allosteric AKT inhibitors, was allowed), and clinically significant abnormalities of 189 
glucose metabolism, defined by any of the following criteria: i) diagnosis of diabetes mellitus 190 
type 1 or 2 (irrespective of management); ii) baseline fasting glucose value of ≥7 mmol/L 191 
(fasting is defined as no calorific intake for at least 8 hours); and iii) glycated hemoglobin 192 
(HbA1c) >8% (>64 mmol/mol). 193 
 194 
All patients provided written informed consent, and the study was performed in accordance with 195 
the Declaration of Helsinki, Good Clinical Practice, and the AstraZeneca policy on bioethics 196 
(36).  197 
 198 
Procedures 199 
Monotherapy patients were treated with capivasertib at the previously determined 200 
recommended Phase II monotherapy dose of 480 mg (34), administered orally, twice daily (bid) 201 
for 4 days on followed by 3 days off, repeated weekly. A treatment cycle was defined as 3 202 
weeks. In the combination cohorts, capivasertib was administered at the previously determined 203 
recommended Phase II combination therapy dose of 400 mg bid, 4 days on, 3 days off, 204 
repeated weekly, in addition to fulvestrant at the labeled dose (37).  205 
 206 
Response assessments were performed by computed tomography (CT) or magnetic resonance 207 
imaging (MRI) every two cycles for 24 weeks, then every 12 weeks until disease progression, 208 
death, or withdrawal. Safety was assessed throughout the study period and until day 28 after 209 
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discontinuation of study treatment according to the National Cancer Institute’s Common 210 
Terminology Criteria for Adverse Events (CTCAE) v4.0. Adverse events were coded with the 211 
Medical Dictionary for Regulatory Activities (MedDRA) v19.1.  212 
 213 
Blood was collected at every study visit for analysis of tumor-derived, cell-free DNA (cfDNA). 214 
AKT1E17K mutation status was assessed in tumor tissue by local testing and/or in cfDNA by 215 
central testing using BEAMing (OncoBEAM™, Sysmex Inostics, Baltimore, MD, USA) (38) and 216 
droplet digital polymerase chain reaction technology (ddPCR) with an allele-specific assay for 217 
both the mutant and the wild-type allele (39). Central NGS was performed retrospectively on 218 
tumor tissue when available, by FoundationOne (40), and on cfDNA using a hybrid capture-219 
based panel covering 300 genes (AZ300).  220 
 221 
Outcomes 222 
The primary study endpoint was safety and tolerability of capivasertib in combination with 223 
fulvestrant. Secondary endpoints included: ORR, defined as a confirmed partial response (PR) 224 
or complete response (CR); duration of response (DOR), defined as the time from confirmed 225 
objective response to disease progression or death; PFS, defined as the time from the first day 226 
of treatment to disease progression or death; and clinical benefit rate at 24 weeks (CBR24), 227 
defined as disease response (PR or CR) or stabilization for ≥24 weeks. Responses were 228 
investigator assessed according to RECIST v1.1 and required confirmation. Patients who 229 
discontinued prior to their first response assessment were considered non-evaluable for best 230 
overall response and non-responders by intent-to-treat analysis. 231 
 232 
Statistical Analysis 233 
All analyses were conducted according to the protocol and statistical analysis plan (and were as 234 
previously reported for the monotherapy cohort) (29). Although the primary endpoint throughout 235 
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this multipart Phase I study remained safety and tolerability, the sample size of the expansion 236 
cohort reported here was determined with the aim of detecting a signal of efficacy, should one 237 
exist, using CBR24. The capivasertib and fulvestrant combination cohorts underwent protocol-238 
specified analyses, conducted independently for each (fulvestrant-naïve and fulvestrant-239 
pretreated) cohort, when 12 patients (at interim analysis) and 24 (at final analysis) per cohort 240 
were evaluable for CBR24 (Figure 1). The sample size was determined based on pre-specified 241 
target values for CBR24 of 65% and 40% for fulvestrant-naïve and fulvestrant-pretreated 242 
patients, respectively (with 24 patients per cohort, there would be a 90% chance of at least 13 243 
and 7 clinical benefit responses, respectively). At interim analysis, enrollment to the fulvestrant-244 
naïve cohort halted, while the fulvestrant-pretreated cohort continued and completed accrual. 245 
Eight subsequent patients who were being screened at the time of closing each cohort were 246 
permitted to enroll, leading to a total of 16 and 28 patients in the fulvestrant-naïve and 247 
fulvestrant-pretreated cohorts, respectively. Final analysis occurred on August 7, 2018, when all 248 
44 patients had had the opportunity to reach 24 weeks of treatment. All patients who received at 249 
least one dose of capivasertib (n=44) were evaluable for safety. Efficacy data are reported for 250 
43 AKT1E17K-mutant patients and exclude one patient enrolled with a non-E17K mutation 251 
(AKT1E40K). 252 
 253 
DOR and PFS were estimated using the Kaplan–Meier method. Patients without a progression 254 
event as of the analysis date were censored at the last known assessment. Post hoc analyses 255 
of endocrine-sensitive and -pretreated subpopulations and of patients treated with ≤2 or ≥3 prior 256 
lines of chemotherapy for MBC were performed. Patients were defined as sensitive to prior 257 
endocrine therapy if they had ≥24 months of endocrine therapy before recurrence in the 258 
adjuvant setting and/or a response or stabilization for ≥6 months of endocrine therapy for 259 
advanced disease. Exploratory biomarker analyses investigated the association between cfDNA 260 
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response, defined as >50% decrease in AKT1E17K-mutant copies/mL plasma from baseline to 261 




Patient Characteristics 264 
Sixty-three AKT1E17K-mutant ER+ MBC patients received capivasertib either as monotherapy 265 
(n=20) or in combination with fulvestrant (n=43; Table 1). The majority of combination therapy 266 
patients were enrolled based on AKT1E17K mutation detection by local laboratory testing of tumor 267 
tissue (77%, 33/43), with the remaining (n=10) patients enrolled through central laboratory 268 
plasma testing. Among patients who received the combination, 28 were previously fulvestrant 269 
pretreated and 15 were fulvestrant naïve. Median age was 57 years (range: 38–76). Most 270 
patients had visceral disease at enrollment (87%) and were heavily pretreated. Overall, 91% of 271 
patients had received prior chemotherapy, 35% mTOR inhibitors, and 24% CDK4/6 inhibitors for 272 
metastatic disease. Only 54% of patients exhibited sensitivity to prior endocrine therapy, defined 273 
by at least 24 months of endocrine therapy before recurrence in the adjuvant setting and/or a 274 
response or stabilization for at least 6 months of endocrine therapy for advanced disease. 275 
However, caution should be exercised in interpreting this seemingly low rate of endocrine 276 
therapy sensitivity compared with rates of ~80% reported in pivotal Phase III trials conducted in 277 
ER+ MBC patients (5, 41), given the retrospective and exploratory nature of this analysis. In 278 
combining both monotherapy and combination therapy cohorts, certain differentiating baseline 279 
characteristics were apparent between the fulvestrant-naïve (n=21) and fulvestrant-pretreated 280 
(n=42) patients. Specifically, a high proportion of fulvestrant-naïve patients were treated with 281 
first-line chemotherapy in the metastatic setting (38% vs 12%, respectively) and had received 282 
fewer total lines of endocrine therapy (median 2 vs 4, respectively).  283 
 284 
Safety 285 
Adverse events (AEs) causally linked to study treatment by the investigator are shown in 286 
Table 2. The most common all-grade AEs for the monotherapy cohort were diarrhea (65%), 287 
nausea (50%), hyperglycemia (45%), and vomiting (45%). Similarly, for the combination cohort, 288 
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the most common AEs were diarrhea (59%), nausea (30%), maculopapular rash (21%), fatigue 289 
(18%), and hyperglycemia (18%). Grade ≥3 AEs attributed to study treatments were observed in 290 
50% of patients in the monotherapy cohort, most commonly hyperglycemia (30%) and 291 
maculopapular rash (20%), and 21% of patients in the combination cohort, most commonly 292 
maculopapular rash (9%). AEs irrespective of causality are shown in Supplementary Table 1. 293 
No new safety signals were identified with the combination of fulvestrant. 294 
 295 
Median duration of capivasertib exposure in the monotherapy cohort and combination cohort 296 
was 166 days (mean daily dose 870 mg) and 123 days (775 mg), respectively. In the 297 
monotherapy cohort, 13 (65%) patients required dose interruption, 7 (35%) dose reduction, and 298 
1 (5%) discontinuation as a result of a treatment-related AE (confusion). In the combination 299 
cohort, 19 (43%) patients required dose interruption, 4 (9%) dose reduction, and 5 (11%) 300 
discontinuation because of an AE (Supplementary Table 2), three of which were treatment 301 
related (eosinophilic pneumonia, fatigue, and rash). There were no treatment-related or AE-302 
attributable deaths in either cohort. 303 
 304 
Efficacy Analyses 305 
At the time of data cut-off, seven patients remained on therapy, the majority having discontinued 306 
because of disease progression (Supplementary Figure 1). Median follow-up (time to event) for 307 
all capivasertib-treated patients who were censored at the time of primary analysis was 8.1 308 
months (range: 0–27.5). Efficacy in the monotherapy cohort and combination cohorts (overall 309 
and by prior fulvestrant therapy exposure) is shown in Table 3 and Figures 2 and 3. Among 310 
patients receiving combination therapy, ORR was 36% (95% CI: 19–56) in fulvestrant-311 
pretreated patients and 20% (95% CI: 4–48) in fulvestrant-naïve patients. ORR in the 312 
monotherapy cohort was 20% (95% CI: 8–58). Across both monotherapy and combination 313 
 15 
 
cohorts (n=63), ORR was 33% (95% CI: 20–50) in fulvestrant-pretreated patients and 14% 314 
(95% CI: 3–36) in fulvestrant-naïve patients. Despite the numerically higher ORRs observed in 315 
the fulvestrant-pretreated patients, CBR24 was broadly similar across groups. Specifically, in the 316 
combination cohort, CBR24 was 50% (95% CI: 31–69) in fulvestrant-pretreated and 47% (95% 317 
CI: 21–73) in fulvestrant-naïve patients. Across both monotherapy and combination cohorts, 318 
CBR24 was 50% (95% CI: 34–66) in fulvestrant-pretreated and 43% (95% CI: 22–66) in 319 
fulvestrant-naïve patients. 320 
 321 
To determine whether additional patient and treatment characteristics could further enrich for 322 
patients who experienced benefit from capivasertib, several exploratory post hoc subgroup 323 
analyses were conducted. Across monotherapy and combination therapy patients, ORR and 324 
CBR24 were numerically higher in patients who had received ≤2 prior lines of chemotherapy 325 
(35% and 62%, respectively) compared with those who had received ≥3 prior lines (22% and 326 
38%, respectively; Supplementary Table 3). Analyses classifying patients based on prior 327 
endocrine therapy sensitivity were also conducted but did not clearly predict benefit of 328 
capivasertib-based therapy. 329 
 330 
Exploratory Biomarker Analyses 331 
Central biomarker assessments in the combination cohort utilized a variety of assays. Central 332 
tissue NGS was performed in 42% (18/43) of patients. BEAMing was used for mutation 333 
detection in plasma cfDNA collected at screening and detected the AKT1E17K mutation in 95% 334 
(41/43) of patients. ddPCR and broader NGS profiling were performed on plasma cfDNA 335 
collected on the first day of treatment (cycle 1 day 1), detecting the AKT1E17K mutation in 80% 336 
(33/41) and 76% (31/41) of patients tested, respectively (Figure 3). These data demonstrate that 337 
plasma-based analyses offer an additional diagnostic opportunity for AKT1E17K mutation testing 338 
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(35). In this cohort, a ≥50% decrease from baseline at cycle 2 day 1 was associated with 339 
improved PFS (Supplementary Figure 2), similar to that previously demonstrated in the 340 
monotherapy cohort (29). 341 
 342 
In 41 patients tested, the broader genetic profiling of plasma samples by NGS identified co-343 
occurring alterations in ESR1 (n=10, almost all in fulvestrant-pretreated patients and all in those 344 
with a detectable AKT1 E17K mutation by plasma NGS), TP53 (n=8, predominantly in fulvestrant-345 
naïve patients), MAP3K1 (n=4), PIK3CA (n=4) and FGFR1 (n=2) (Figure 3). In one of the 346 
PIK3CA-mutant cases, despite an AKT1E17K mutation being detected by BEAMing at a very low 347 
mutant allele fraction (MAF), the AKT1E17K mutation was not in fact detectable by NGS, 348 
indicative of the subclonality of the alteration in this patient (Supplementary Figure 3). Evidence 349 
of a subclonal AKT1E17K mutation could also be found in another patient, in whom the AKT1E17K 350 
mutation was detected by BEAMing and ddPCR but not by the NGS analysis that detected other 351 
somatic mutations in this patient. While 8 (20%) patients did not shed sufficient circulating tumor 352 
DNA for mutation detection by NGS (ie low shedders), in all other (31; 94%) patients, the 353 
AKT1E17K mutation was detected at a level around or above the median MAF indicative of the 354 
predominantly clonal nature of this alteration (Figure 3 and Supplementary Figure 3). In this 355 
limited sample set, no obvious pattern in AKT1E17K clonality or co-incident tumor mutations was 356 
associated with clinical outcome, although, potentially of interest, 6 of the 8 (75%) cases 357 
identified as low shedders by NGS had an objective response, and none of the patients whose 358 
tumors harbored a TP53 mutation achieved an objective response. While the sample size was 359 
small, the observed higher frequency of TP53 mutations in the fulvestrant-naïve compared with 360 
the fulvestrant-pretreated cohort (33% vs 12%, respectively) potentially supports the 361 
observation that this group had more aggressive disease biology (42). Equally, the identified 362 
TP53 mutations could be related to the greater degree of cytotoxic chemotherapy exposure in 363 




In this multicohort Phase I study, we sequentially explored the safety and efficacy of the pan-366 
AKT inhibitor capivasertib, initially alone and later in combination with fulvestrant, in ER+ 367 
AKT1E17K-mutant MBC patients. The safety profile was similar to that in prior reports (29, 34, 45), 368 
although combination therapy appeared better tolerated, likely because of the lower dose of 369 
capivasertib (400 mg bid 4 days on, 3 days off) administered with fulvestrant compared with the 370 
monotherapy dose of capivasertib (480 mg bid 4 days on, 3 days off), as suggested by the 371 
dose–response relationship observed for key capivasertib-related toxicities such as 372 
hyperglycemia (46).  373 
 374 
Although the study was not designed to directly compare activity across groups, and noting that 375 
the fulvestrant-naïve (n=21) patients treated in this study may have had a more aggressive 376 
disease profile at baseline than those who were fulvestrant pretreated (n=42), optimal efficacy 377 
was nonetheless observed with combination therapy, specifically in fulvestrant-pretreated 378 
patients (ORR 36%; CBR24 50%). Taken together, these findings are encouraging, particularly 379 
given the heavily pretreated nature of the study population. There is also reason to believe that 380 
our data compare favorably with prior reports on molecular therapy in the clinic. For example, 381 
BELLE-3 evaluated fulvestrant, with or without the pan-PI3K inhibitor buparlisib, in mTOR-382 
inhibitor-exposed patients, reporting, respectively, an ORR of 8% versus 2% and CBR24 of 25% 383 
versus 15% (47). This provides a useful benchmark for fulvestrant monotherapy following 384 
mTOR inhibitor exposure in a notably less pretreated (no more than one line of chemotherapy 385 
and no prior fulvestrant were permitted) population. Similarly, our data compare favorably with 386 
expected chemotherapy outcomes in endocrine-resistant patients (48).  387 
 388 
The benefit of adding capivasertib to hormone therapy in AKT1E17K-mutant patients is consistent 389 
with preclinical data (32). More broadly, the role for co-targeting ER and PI3K pathway 390 
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alterations has been demonstrated in multiple randomized, Phase III studies of PI3K inhibitors 391 
(17, 49). Furthermore, in the recently reported randomized Phase II FAKTION study, the 392 
addition of capivasertib to fulvestrant showed a significant improvement in PFS in a molecularly 393 
unselected, aromatase-inhibitor-pretreated but fulvestrant-naïve ER+ MBC population (50). 394 
Given the increasing genomic complexity of breast cancer as it advances through multiple lines 395 
of therapy, this recent trial report supports our observation and hypothesis, and others’, that 396 
earlier introduction of targeted therapies to a less clonally diverse disease is likely to be 397 
necessary to garner significant improvements in outcome in patients harboring these driver 398 
oncogenic alterations (14).  399 
 400 
Acknowledging that only 24% of enrolled patients in this study received prior CDK4/6 inhibitors, 401 
agents that are now standard of care in combination with an aromatase inhibitor or fulvestrant in 402 
the first- or second-line setting, these data remain of interest. Outcomes of targeted therapy 403 
following CDK4/6 inhibitor exposure in ER+ MBC are largely unknown. However, preclinical 404 
models with acquired resistance to CDK4/6 inhibitors do indicate retained sensitivity to PI3K 405 
pathway inhibition combined with endocrine therapy (51, 52). Indeed, in SOLAR-1, the small 406 
subset of patients with prior CDK4/6 inhibitor exposure did still appear to derive benefit from the 407 
addition of apelisib to fulvestrant (17). Additionally, of interest, recent preclinical data have 408 
implicated PTEN loss, as a potential mechanism of resistance to CDK4/6 inhibitors, via 409 
increased AKT activation in vitro and in vivo (53), a hypothesis since observed in the clinic 410 
where enrichment of PTEN loss-of-function alterations has been described in tumor samples 411 
obtained after CDK4/6 inhibitor therapy (54). Intriguingly, in this context (PTEN-null models 412 
resistant to CDK4/6 inhibitors), AKT inhibition may in fact be superior to PI3K inhibition (53). It is 413 
also clear from preclinical work that constitutively active AKT induces resistance to PI3K 414 
inhibition in breast cancer cell lines, and, interestingly, increased AKT1 expression was 415 
identified in a very small cohort of biopsies collected post-treatment with alpelisib (55). Clinical 416 
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data demonstrating a role for AKT1 mutations mediating resistance to anti-estrogens or CDK4/6 417 
inhibitors are limited. A recent clinical series (n=57) noted an over-representation of PI3K 418 
pathway mutations (PIK3CA, AKT1, TSC2, and/or loss or truncation mutations of PTEN) among 419 
patients with a poor response to neoadjuvant letrozole (Pre-operative Endocrine Prognostic 420 
Index [PEPI] >4 and/or recurrence), although this was unlikely to be driven by AKT1, as none of 421 
the three AKT1-mutant cases in this report experienced a recurrence and two of the three were 422 
actually categorized in the responder group (PEPI <4 and no recurrence) (56). Additionally, an 423 
endocrine-therapy-exposed ER+ breast cancer dataset did not identify AKT1 mutations in 424 
tumors intrinsically resistant to letrozole; rather, AKT1 mutations were detected in those 425 
sensitive to the therapy (57, 58). In agreement with this, genomic profiling of a large (n=1501) 426 
cohort of endocrine-therapy-naïve versus endocrine-therapy-exposed ER+ breast cancers did 427 
not show any evidence of AKT1 mutations being associated with resistance to hormonal therapy 428 
(15). Finally, findings from a recent institutional dataset (n=58) have proposed activating events 429 
in AKT1 as a possible mechanism of resistance to therapy containing CDK4/6 inhibitors, along 430 
with in vitro data showing overexpression of AKT1 as conferring resistance to CDK4/6 inhibitors 431 
(50), although, thus far, this has not been observed in genomic analysis from the registration 432 
studies of these agents (59, 60). Moreover, genomic analysis of 348 ER+ breast cancers 433 
treated with CDK4/6 inhibitors, as well as comparative analysis of tumors before (n=838) versus 434 
after (n=221) CDK4/6 inhibitor therapy, along with paired analysis of tumors before versus after 435 
CDK4/6 inhibitor therapy (n=210), has not identified an association between AKT1 mutations 436 
and therapeutic resistance to CDK4/6 inhibitors (54, 61). 437 
 438 
Our study has several important limitations. Firstly, this trial was not formally powered to 439 
compare efficacy across treatment groups. Secondly, although efficacy appeared most robust in 440 
fulvestrant-pretreated patients, it is noteworthy that the fulvestrant-naïve patients enrolled here 441 
appeared to be a subgroup with poorer prognosis. Given this, we cannot rule out the role that 442 
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demographic imbalance between the groups driven by adverse patient selection factors may 443 
have played in the apparent difference in treatment outcomes. Thirdly, we do not know the 444 
extent to which the presence of an AKT1E17K mutation may influence the natural history or 445 
response to standard therapy for MBC. Despite this, recent analyses suggest that prognoses of 446 
AKT1E17K-mutant and wild-type MBC patients appear largely comparable, somewhat mitigating 447 
this concern (21). Finally, despite opening this study at 16 sites internationally, the rarity of this 448 
biomarker led to slow accrual (22 months to enroll 44 patients in the combination cohort), 449 
despite having central screening by BEAMing in plasma implemented, in addition to local 450 
testing.  451 
 452 
In conclusion, this study demonstrates that AKT1E17K is a clinically relevant, valid target in ER+ 453 
breast cancer and that the AKT inhibitor capivasertib is tolerable and active as both 454 
monotherapy and in combination with fulvestrant, including in patients with prior fulvestrant 455 
resistance. We confirm that the majority of enrolled patients had detectable AKT1E17K in plasma 456 
at baseline and demonstrate the feasibility of enrollment based on centralized plasma screening 457 
for this rare genomic biomarker (35). With other genomic biomarkers such as PIK3CA mutations 458 
expected to become part of routine management paradigms over the coming years in breast 459 
cancer, these data have the prospect of becoming part of a rationale to incorporate other 460 
potentially actionable alterations in breast cancer, including ERBB2 and AKT1, into diagnostic 461 
testing algorithms and for the early identification of these alterations in the metastatic disease 462 
course (62, 63). Finally, data from this study, along with the FAKTION study, have provided the 463 
basis for a confirmatory Phase III study that will take into account populations with and without 464 
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Median age, years (range) 57 (38–71) 58 (42–76) 56 (40–73) 57 (39–76) 57 (38–73) 57 (38–76) 
Female gender, n (%) 20 (100) 15 (100)  28 (100) 21 (100) 42 (100) 63 (100) 
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ER+ and PR+, n (%)
 
ER+ and PR–, n (%) 

























Visceral disease, n (%) 20 (100)  12 (80) 23 (82)  18 (86) 37 (88) 55 (87)  
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42 (67)  
Prior sensitivity to endocrine therapy, n (%)
d
 11 (55) 7 (47) 16 (57) 10 (48) 24 (57) 34 (54) 
Prior chemotherapy for metastatic disease, 
n (%) 
19 (95) 12 (80) 26 (93) 17 (81) 40 (95) 57 (91) 
Chemotherapy as first-line therapy in the 
metastatic setting, n (%) 
5 (25) 6 (40) 2 (7) 8 (38) 5 (12) 13 (21) 
Prior CDK4/6 inhibitor, n (%) 3 (15) 1 (7) 11 (39) 2 (10) 13 (31) 15 (24) 
Prior mTOR inhibitor, n (%) 11 (55) 2 (13) 9 (32) 4 (19) 18 (43) 22 (35) 
Prior P13K inhibitor, n (%) 1 (5) 1 (7) 4 (14) 1 (5) 5 (12)  6 (10) 
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 patient, who was enrolled based on an AKT1
E40K
 mutation detected by local NGS; 
b
Includes both primary 
and metastatic biopsy; 
c
Inclusive of adjuvant or metastatic therapies; 
d
Defined by at least 24 months of endocrine therapy before recurrence in the 
adjuvant setting and/or a response or stabilization for at least 6 months of endocrine therapy for advanced disease. ECOG, Eastern Cooperative 





Table 2. AEs Causally Linked to Study Treatment (>10% of Patients) and Grade ≥3 AEs 
(>2 Patients)  
















 All grades Grade ≥3 All grades Grade ≥3 All grades Grade ≥3 
Any AE (causally 
related to 
capivasertib), n (%) 
19 (95) 10 (50) 38 (86) 9 (21) 57 (89) 19 (30) 
Diarrhea 13 (65) 2 (10) 26 (59) 2 (5) 39 (61) 4 (6) 
Nausea 10 (50) 0 13 (30) 1 (2) 23 (36) 1 (2) 
Hyperglycemia 9 (45) 6 (30) 8 (18) 2 (5) 17 (27) 8 (13) 
Vomiting 9 (45) 0 7 (16) 0 16 (25) 0 
Fatigue 8 (40) 0 8 (18) 1 (2) 16 (25) 1 (2) 
Rash maculopapular 6 (30) 4 (20) 9 (21) 4 (9) 15 (23) 8 (13) 
Decreased appetite 3 (15) 0 7 (16) 1 (2) 10 (16) 1 (2) 
Stomatitis 4 (20) 0 6 (14) 0 10 (16) 0 
Dry skin 4 (20) 0 3 (7) 0 7 (11) 0 
Abdominal pain 4 (20) 0 2 (5) 0 6 (9) 0 
Dizziness 4 (20) 0 2 (5) 0 6 (9) 0 
Pruritus 3 (15) 0 3 (7) 0 6 (9) 0 
Dry mouth 4 (20) 0 0 0 4 (6) 0 
Includes AEs with an onset date on or after the date of first dose and up to and including 28 days 





 patient excluded from the efficacy analyses, who was enrolled based on an AKT1
E40K
 
mutation detected by local NGS. AE, adverse event; NGS, next-generation sequencing. 
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Capivasertib + Fulvestrant 
Combination (N=43) 




















ORR, % (95% CI) 
Complete response, n (%) 
Partial response, n (%) 
































13 (21) Stable disease 24 weeks, n (%) 4 (27) 4 (14) 6 (29) 7 (17) 






47 (21–73) 50 (31–69) 43 (22–66) 50 (34–66) 48 (35–61) 
 
Median PFS, months (95% CI) 5.4 (3–7) 5.6 (2–14) 5.0 (3–8) 5.4 (3–10) 5.0 (4–7) 5.4 (4–7) 
Response is based on investigator tumor assessments in accordance with RECIST v1.1 in patients with measurable disease. 
a
Confirmed no fewer 
than 4 weeks after the criteria for response were initially met; 
b
Clinical benefit defined as confirmed best overall response of complete response, 
partial response, or stable disease for at least 24 weeks. CI, confidence interval; DOR, duration of response; ER, estrogen receptor; HER2, human 




Figure 1. Study Design of the ER+ AKT1-Mutant Breast Cancer Patient Cohorts  
The breast cancer cohorts were part of a larger open-label, multipart, Phase I study of the first-in-human 
evaluation of oral capivasertib in patients with advanced solid malignancies. These Phase I expansion 
cohorts were non-randomized; the monotherapy cohort enrolled first, followed by the combination therapy 
cohort. Protocol-specified analyses planned for each study part: For monotherapy, analyses were 
planned after 20 patients were followed up for 12 weeks/withdrawn from the study. For combination 
therapy, interim analysis was planned after 12 patients in each cohort were followed up for 24 
weeks/withdrawn from the study, and final analysis was planned after up to 24 patients in total in each 
cohort were followed up for 24 weeks/withdrawn from the study. 
a
Up to 120. CBR24, clinical benefit rate at 
24 weeks; ER, estrogen receptor; ORR, objective response rate; PFS, progression-free survival. 
 
Figure 2. Efficacy of Capivasertib Monotherapy in ER+ AKT1E17K-Mutant MBC (n=20) 
Plot based on patients with available RECIST data at baseline and at least one follow-up assessment. 
Investigator-assessed best percentage change from baseline was the change in the sum of longest 
diameters of target lesions. BoR, best objective response; ER, estrogen receptor; MBC, metastatic breast 
cancer; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors. 
 
Figure 3. Combined Efficacy and Biomarker Data From the Combination Therapy 
(Capivasertib + Fulvestrant) Cohort in ER+ AKT1E17K-Mutant MBC (n=43) 
Best RECIST response and associated PFS integrated with genomic analyses for all 43 patients enrolled 
in the combination cohorts. Top to bottom: prior exposure to a CDK4/6 inhibitor; best objective response; 
best change from baseline in target lesion diameter according to RECIST v1.1; PFS in months; AKT1
E17K
 
mutation detection at baseline by various testing platforms (BEAMing, ddPCR, NGS) in tissue and/or 
ctDNA, and at C2D1 by ddPCR in ctDNA; and percentage change (≥50% decrease) in AKT1
E17K
-mutant 
copies in ctDNA by ddPCR measured on C2D1 of study treatment compared with baseline (C1D1). For 
33 patients with somatic mutations detected in ctDNA by NGS, the AKT1
E17K
 MAF, as well as the MAF 
from other key alterations, is presented together with the median MAF of all somatic mutations detected 
in each sample. Two patients lacked genomic data (not tested), and eight patients had no somatic 
 38 
 
mutations detected in their ctDNA samples by NGS, although they did by the more sensitive 
OncoBEAM™ and/or ddPCR assays and were deemed low shedders. Key co-occurring gene mutations 
detected by NGS analysis in ctDNA samples are indicated in the genomic heat map at the bottom of the 
figure. AF, allele frequency; C1D1, cycle 1 day 1; C2D1, cycle 2 day 1; ctDNA, circulating tumor DNA; 
ddPCR, droplet digital polymerase chain reaction; ER, estrogen receptor; FMI, Foundation Medicine, Inc; 
MAF, mutant allele fraction; MBC, metastatic breast cancer; NGS, next-generation sequencing; PFS, 
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64 patients identified with AKT mutations
• 63 AKT1E17K mutant 
• 1 non-AKT1E17K mutanta
1 patient ongoing 
treatment at data cut-off
1 patient ongoing 
treatment at data cut-off
20 received treatment (FAS)
19 patients discontinued 
treatment:
• 11 progressive 
disease
• 2 adverse events
• 3 patient decision
• 3 other
Capivasertib monotherapy Capivasertib and fulvestrant combination
44 received treatmenta
aThe non-AKT1E17K-mutant patient was enrolled based on an AKT1E40K mutation detected by local NGS; this patient was 
excluded from the efficacy analyses. FAS, full analysis set; NGS, next-generation sequencing.
23 patients discontinued 
treatment
• 14 progressive 
disease
• 4 adverse events






5 patients ongoing 
treatment at data cut-off
15 patients discontinued 
treatment:
• 11 progressive 
disease
• 1 adverse events
• 1 patient decision
• 2 other
Supplementary Figure 1. Participant Flow Diagram
A ≥50% decrease in circulating AKT1E17K at cycle 2 day 1 compared with baseline (cycle 1 day 1), as measured by ddPCR, was 
associated with improved PFS on treatment. ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction; 
PFS, progression-free survival.
Supplementary Figure 2. PFS Association With ≥50% Decrease from Baseline in 
AKT1E17K at Cycle 2 Day 1 in ctDNA
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Supplementary Table 1. Adverse Events Irrespective of Causality Occurring in >10% of 
Patients 












Any AE (irrespective 
of causality) 
20 (100) 43 (97.7) 63 (98.4) 





Grade ≥3 All 
grades 
Grade ≥3 All 
grades 
Grade ≥3 
Diarrhea 13 (65) 2 (10) 28 (64) 2 (5) 41 (64) 4 (6) 
Nausea 11 (55) 0 23 (52) 2 (5) 34 (53) 2 (3) 
Vomiting 9 (45) 0 11 (25) 1 (2) 20 (31) 1 (2) 
Hyperglycemia 10 (50) 7 (35) 9 (21) 3 (7) 19 (30) 11 (17) 
Fatigue 8 (40) 0 10 (23) 1 (2) 19 (28) 1 (2) 
Decreased appetite 4 (20) 0 14 (32) 1 (2) 18 (28) 1 (2) 
Rash 
maculopapular 
7 (35) 4 (20) 10 (23) 5 (11) 17 (27) 9 (14) 
Back pain 6 (30) 0 9 (21) 2 (5) 15 (23) 2 (3) 
Abdominal pain 7 (35) 1 (5) 7 (16) 0 14 (22) 1 (2) 




aminotransferase   
increased 
3 (15) 2 (10) 8 (18) 2 (5) 11 (17) 4 (6) 
Dizziness 5 (25) 0 5 (11) 0 10 (16) 0 




3 (15) 3 (15) 6 (14) 3 (7) 9 (14) 6 (9) 
Pruritus 3 (15) 0 6 (14) 0 9 (14) 0 
Pyrexia 3 (15) 0 6 (14) 0 9 (14) 0 
Asthenia 1 (5) 0 7 (16) 0 8 (13) 0 
Cough 3 (15) 0 5 (11) 0 8 (13) 0 
Headache 4 (20) 1 (5) 4 (9) 1 (2) 8 (13) 2 (3) 
Dry skin 4 (20) 0 4 (9) 0 8 (13) 0 
Arthralgia 1 (5) 0 6 (14) 0 7 (11) 0 




1 (5) 1 (5) 5 (11) 0 6 (9) 1 (2) 
Dry mouth 5 (25) 0 1 (2) 0 6 (9) 0 
Constipation 3 (15) 0 3 (7) 0 6 (9) 0 
Neutrophil count 
decreased 
0 0 5 (11) 1 (2) 5 (8) 1 (2) 
Weight decreased 0 0 5 (11) 0 5 (8) 0 
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Hypertension 2 (10) 0 3 (7) 1 (2) 5 (8) 1 (2) 
Myalgia 4 (20) 0 1 (2) 0 5 (8) 0 
Includes AEs with an onset date on or after the date of first dose and up to and including 28 days following 

















Supplementary Table 2. Treatment Exposure, Dose Modifications and Dose Discontinuation of Capivasertib for the 














Mean capivasertib relative dose 
intensity (SD)b 
93 (29) 92 (11) 96 (23) 94 (20) 
Mean daily dose, mgc 870 762 783 775 










Median total capivasertib treatment 









Median actual capivasertib 









Patients with a dose interruption 
and/or modification, n (%) 
13 (65) 11 (69) 
 
11 (39) 22 (50) 
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Any AE leading to dose interruption 
of capivasertib (irrespective of 
causality), n (%) 
11 (55) 9 (56) 10 (36) 19 (43) 
Any AE leading to dose reduction of 
capivasertib (irrespective of 
causality), n (%) 
7 (35) 2 (13) 2 (7)  4 (9) 
Any AE leading to discontinuation 
of capivasertib (irrespective 
of causality), n (%) 
1 (5) 1 (6) 4 (14) 5 (11) 
aAE data for Part D have been reported previously (1); bRelative dose intensity is actual dose intensity delivered relative to intended dose intensity 
up to progression or actual last dosing day; cMean daily dose = total dose/actual treatment duration; dTotal treatment duration = last dose date on 
which dose >0 mg – first dose date + 1; eActual treatment duration = total treatment duration, excluding dose interruptions and planned ‘no dose’ 






Supplementary Table 3. Exploratory Subgroup Analysis of Treatment Efficacy for Patients 
With ER+ HER2– AKT1E17K-Mutant Metastatic Breast Cancer by Number of Prior Lines of 
Chemotherapy for Metastatic Breast Cancer 
 All Capivasertib-Treated Patients  
(Monotherapy Breast-Specific Cohort + 
Combination Therapy Cohort)  
 ≤2 Prior Lines 
(n=26) 
≥3 Prior Lines 
(n=37) 
ORR, % (95% CI)a 35 (17–56) 22 (10–38) 
CBR, % (95% CI)b 62 (41–80) 38 (23–55) 
Median PFS, months (95% CI) 9 (4–15) 4 (3–6) 
aConfirmed no fewer than 4 weeks after the criteria for response were initially met; bClinical benefit defined 
as confirmed best overall response of complete response, partial response, or stable disease for at least 
24 weeks. CBR, clinical benefit rate; CI, confidence interval; ER, estrogen receptor; HER2, human 
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